
CAMP4 and GSK advance RNA-based therapeutic discoveries
GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration… Read More


